Allakos Inc

NASDAQ ALLK

Data sourced from

and

Download Data

Allakos Inc Dividends Paid 5 year CAGR for the quarter ending September 19, 2024

Allakos Inc Dividends Paid 5 year CAGR is NA for the quarter ending September 19, 2024. Dividends Paid are the cash payments made by a company to its shareholders as a distribution of profits. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

NASDAQ: ALLK

Allakos Inc

CEO	Dr. Robert Alexander Ph.D.
IPO Date	July 19, 2018
Location	United States
Headquarters	975 Island Drive, Redwood City, CA, United States, 94065
Employees	131
Sector	Healthcare
Industry	Biotechnology

Description

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Key trends